Drug Profile
BTL-slo
Alternative Names: BTL slo; BTL-slo/stcfLatest Information Update: 28 Oct 2021
Price :
$50
*
At a glance
- Originator Beech Tree Labs
- Class Exotoxins; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease; Joint disorders
Most Recent Events
- 28 Oct 2021 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in USA
- 28 Oct 2021 No recent reports of development identified for preclinical development in Joint-disorders in USA (IV, Injection)
- 08 Sep 2017 Beech Tree Labs has patent protection for BTL-slo/stcf for Chronic obstructive pulmonary disease in USA, with corresponding pending applications in other regions (Beech Tree Labs website, September 2017).